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There has been a dramatic increase in the incidence of 
diabetes mellitus (DM) worldwide, which has been 
triggered by the growing obesity problem. In 1985, the 
World Health Organization (WHO) estimated that 30 
million people worldwide had some form of diabetes; by 
2000, the number had increased to 177 million. 
Blindness as a secondary effect of diabetes mellitus is 
predominantly caused by diabetic macular edema (DME). 
By 2030, the incidence of DME is estimated to increase to 
100 million (1). Although DME resolves spontaneously in 
approximately 35% of cases after six months (2), 
treatment regimens for the remaining 65% have become 
an important focus of study. 
Diabetic macular edema treatments have changed in 
recent years after the introduction of intravitreal 
injections of anti-vascular endothelial growth factor 
(VEGF) (ranibizumab, bevacizumab, pegaptanib and the 
most-recent introduction of aflibercept), corticoids 
(triamcinolone or dexamethasone), and the sustained 
delivery fluocinolone acetonide vitreous inserts. All these 
new drugs are becoming more popular as the first line of 
treatments worldwide, but this also makes treatment 
more expensive. A combination of laser 
photocoagulation (LP) and intravitreal drugs is being 
investigated to find out whether such treatment might 
be just as effective and reduce costs, since LP alone 
seems to have lost popularity. 
The lasers being used currently are solid lasers obtained 
from frequency-doubled diode or frequency-doubled 
Yttrium Aluminium Garnet (YAG), which emit at a 
wavelength of 532 nm, similar to those with the dry 
yellow-green to argon (514 nm) and the Krypton yellow 
(568 nm). Compared to the argon laser, the doubled 
diode or YAG lasers have a higher absorption in 
oxyhemoglobin (HbO) and hemoglobin (Hb), lesser 
dispersion (because of the long wavelength) and low 
absorption in xanthophyll. Other lasers, such as the 810 
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nm diode laser, are also being studied but will not be the 
focus of this present report. 
What Is the Current Place of Lasers in Treating DME? 
The laser has been the gold standard treatment option in 
comparative studies of intravitreal drugs used in DME 
treatments. Its effect was studied by the Early Treatment 
Diabetic Retinopathy Study (ETDRS) group during the 
1990s and demonstrated that at 36 months: 
• 65% of eyes of patients who had no laser treatment 
lost >15 letters on the Snellen chart, 
• 33% of eyes of patients submitted for deferral LP lost 
>15 letters, and 
• 13% of eyes of patients submitted to immediate laser 
treatment loss vision for >15 letters. 
The study concluded that immediate laser treatment was 
effective in eyes with DME (3). From those results, LP 
became the treatment of choice, and all new treatments 
are being compared to those results. One important 
finding of the ETDRS group was the report on the effect 
of LP over time, showing that eyes of patients with 
clinically significant macular edema (CSME) increased in 
visual acuity (VA) by about 1% the first year, 6% at 24 
months and achieved an improvement of 10% at 36 
months following treatment. We can conclude that the 
laser was effective in treating DME and that the results 
were still relevant 36 months later. Thus, this timeframe 
of three years should be bared in mind whenever 
conclusions on whether a treatment is effective in 
patients with DME are made. 
 
Which Laser Technique Should We Use? 
The ETDRS group explained the two most important 
techniques of LP in patients with DME: the focal, for focal 
DME cases and the grid laser technique for the diffuse or 
more severe forms of DME. 
They, furthermore, explained that a typical focal laser 
treatment entails mild, white burning beneath all of the 
leaking microaneurysms (MA) and other sites of focal 
leakage. A laser beam inflicts a burn raging in size from 
50 to 100 µm by the duration for 0.05 to 0.1 seconds. It is 
important; however, not to burn within 500 µm of the 
center of the macula. A leaking MA is an area of retinal 
thickening on between 500 and 3000 µ from the center 
of the macula. A modified focal laser technique was 
introduced by Diabetic Retinopathy Clinical Research 
Network Group (DRCR.net group), which identified the 
same spot size (50 µm) and duration (0.05 to 0.1 
seconds) to be incorporated into their guidelines, except 
direct whitening of the MS that was not required, and 
only a grayish lesion was recommended. 
For grid treatment, the ETDRS suggested applying laser 
to diffuse leakages or nonperfusion within the following 
areas: 500 to 300 µm superiorly, nasally and inferiorly as 
well as 500 to 3500 µm temporally from the center of the 
macula. Attention should again be laid not to burn 500 
µm within the center of the macula (4), respecting cells 
of the papillomacular bundle. The DRCR.net group (5) did 
include a minimal width apart two burns, as well. 
 
What Complications Should We Expect After Laser 
Treatment? 
Laser photocoagulation is not a safe technique as there 
are side effects possibly to occur after the burn. In 
particular, destruction of the retinal pigment epithelium 
may induce apoptosis of the surrounding retinal cells; 
moreover, those constituting macular area, what can 
ultimately affect VA. One of the most important effects 
that can reduce VA is the enlargement of a laser scar, 
referred to as atrophic creep, which represents a threat 
for eyesight prognosis if the laser has been applied too 
near the fovea. Schatz et al. (6) reported that enlarged 
laser scars reached the central fovea in eyes of 11 of 203 
patients following grid LP for DME. Shah et al. (7) 
observed an expansion of laser scars in a subgroup of 18 
patients at a 2-year follow-up visit, the average 
chorioretinal scar having expanded 50.1% per year in the 
first two years, and 4.6% per year thereafter. 
 
What Causes the Expansion of Laser Scars? 
One can speculate that because of their density, same 
spot size of LP destroyes more photoreceptors in the 
posterior pole than in the mid periphery. Furthermore, 
the photoreceptors cross-talk with each other through 
horizontal or amacrine cells, so necrosis of regional 
photoreceptors might lead to apoptosis of surrounding 
cells, possibly causing laser scars to gradually expand at a 
higher rate in the posterior pole. This expansion rate was 
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even higher four years after treatment and lasers with 
lengthier wavelengths contribute to larger areas of 
chorioretinal atrophy in comparison to lasers with 
shorter wavelengths. 
 
Are There any Other Complications of Laser? 
If the laser burn affects the Bruch’s membrane, a 
choroidal neovascular membrane can grow underneath 
the neurosensory retina in the burn scar. This serious 
complication might be due to the use of repeated, small-
size, short-duration lasers or intense laser burns, or both. 
These membranes can enlarge and reduce VA secondary 
to destruction of the retina, luckily, they respond well to 
intravitreal anti-VEGF agents (8). Finally, other secondary 
effects generally involve retina, such as photophobia or 
the appearance of scotomas in the visual field. 
 
So, What Place Does The Laser Currently Have in DME 
Treatment? 
The Royal College of Ophthalmologists (RCO) describes 
that: “overall, photocoagulation reduces the risk of 
moderate visual loss (defined as a doubling of the visual 
angle, equivalent to a loss of about two Snellen lines) by 
50-70%. However, it is clear that photocoagulation 
therapy does not lead to an improvement in vision per se 
and while it reduces the risk of visual loss in the majority 
of patients, particularly those with PDR [proliferative 
diabetic retinopathy (PDR)], a significant proportion do 
not benefit from photocoagulation, especially for 
macular disease”. The RCO assigned an Evidence Level 1 
to macular LP (focal or grid laser) when VA is reduced to 
20/32 or less (9). 
All studies of diabetic macular LP were referenced in the 
large ETDRS series study, but this study had some 
limitations based on the description of the treated DME 
types. For example, the ETDRS did not compare their 
laser treatment parameters to other therapies for DME, 
nor did the macular laser treatment described by ETDRS 
differentiate between focal and grid laser treatments. 
Finally, the treated lesions were identified using 
fluorescein angiography despite macular LP being the 
gold standard for DME treatment. 
In the 21st century, the principal treatment indication for 
LP is for those edemas that affect the macular region 
without involvement of the CSME. Some patients who 
have lesions in CSME and low VA also have DME without 
a predominant MA as the focus. In these cases, some 
clinicians prefer intravitreal injections as first-line 
therapy and others favor the grid laser. 
Generally, the grid laser seems to be used only in cases 
of DME that are unresponsive to intravitreal drugs. In 
these chronic cases that have difficulty responding to 
anti-VEGF treatment and corticoids, the grid laser seems 
to be of benefit, but the small improvement achieved in 
most cases makes it a poor option in the treatment of 
DME. 
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